Open AccessAzilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension
Author(s) -
Megha Sood,
Jagminder Kaur Bajaj,
Jagminder Kaur Bajaj
Publication year - 2018
Publication title -
international journal of medical and dental sciences
Language(s) - English
Resource type - Journals
eISSN - 2454-8952
pISSN - 2320-1118
DOI - 10.18311/ijmds/2013/19830
Subject(s) - medicine , tolerability , atrial fibrillation , blood pressure , angiotensin receptor , coronary artery disease , cardiology , angiotensin receptor blockers , angiotensin ii , heart failure , disease , renin–angiotensin system , adverse effect
Hypertension is an important risk factor for cardiovascular and renal disease. It’s early detection and control is critically important as it is an important attributable cause of stroke, coronary artery disease, heart failure, atrial fibrillation and ESRD. Recent data indicates increasing prevalence of hypertension amongst various populations. This reflects the importance of having a variety of treatment options for the management of this condition. Angiotensin receptor blockers are highly effective at reducing blood pressure, have excellent tolerability and renoprotective properties, hence they remain a useful choice in the management of hypertension. Azilsartan medoxomil has recently been approved by the FDA for the oral treatment of hypertension making it the eighth Angiotensin receptor blocker to be approved for this indication.